Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of oral RO7020531 in healthy volunteers and virologically suppressed chronic hepatitis B patients
NL-OMON55546Phase 1Active, not recruiting
- Sponsor
- Covance
- Start
- Apr 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ruzotolimod in Chronic Hepatitis B (CHB) (4 arms), sponsored by Covance. Primary endpoints: Incidence and severity of adverse events, Incidence of laboratory abnormalities and 1 more. Started Apr 2018; status: active, not recruiting.
02
Drugs
ruzotolimod
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON55546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55546.